Sage Bionetworks

DATAcc by DiMe Launches Core Measures for Sleep

Retrieved on: 
Wednesday, April 24, 2024
J&J, Defense Innovation Unit, Sage Bionetworks, Parkinson's disease, TC, Eli Lilly and Company, Boston University, Drug development, Veterans' affairs, Health, National Sleep Foundation, Partnership, Jazz Pharmaceuticals, Research, EHealth, Roche, Alzheimer's disease, Environment, Disease, Duke University, UCB, Medical device, Digital health, Government, GSK, MindMed, Mental health, Patient, TNO, Dime, PD, Dementia, Pharmaceutical industry

BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) released a core set of digital measures and resources for sleep. Together, these will increase the availability of high-quality, standardized, and transparent sleep assessments in a natural environment and transform research and care to advance overall population health. The core digital measures set and resources were developed by a cross-disciplinary group of experts designed to maintain broad applicability across research, care, and multiple disease areas.

Key Points: 
  • BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community ( DATAcc ) by the Digital Medicine Society ( DiMe ) released a core set of digital measures and resources for sleep .
  • Better sleep means better health, and disrupted sleep can indicate or cause chronic conditions ranging from primary sleep disorders to mental health conditions to Parkinson's Disease to Women's health to cardiac conditions and more.
  • "The core digital measures of sleep and accompanying resources now make it more accessible than ever before to incorporate sleep data into trials and care plans where sleep was previously inaccessible.
  • In addition to the core measures and over 15 new resources, the project team also added sleep digital measurement products to the Library of Digital Measurement Products.

March of Dimes Global Crowdsourcing Effort Yields Pair of Predictive Models for Preterm Birth

Retrieved on: 
Thursday, December 21, 2023
DREAM, Biology, Infant, Database, Stanford University, Pregnancy, Risk assessment, Risk, Infection, Division, Imperial College London, Data analysis, Research, Internal medicine, Wayne State University, Data, Health, Disease, Pediatrics, Preterm birth, Patent, University, Machine learning, OB/GYN, Dime, Collaboration, Bangladesh Technical Education Board, Manuscript, NIH, Sage Bionetworks, Bacteria, Vagina, UCSF, Data wrangling, Pharmaceutical industry

The 2023 March of Dimes Report Card shows that the U.S. preterm birth rate stands at 10.4%, a meager improvement from last year's historic high of 10.5%, the highest preterm birth rate in 10 years.

Key Points: 
  • The 2023 March of Dimes Report Card shows that the U.S. preterm birth rate stands at 10.4%, a meager improvement from last year's historic high of 10.5%, the highest preterm birth rate in 10 years.
  • Key to the predictive models is their ability to estimate a woman's risk for two types of preterm birth—one before 37 weeks and the other before 32 weeks.
  • The models' predictive power was strong: One predicted preterm birth with a 69% accuracy, and the other predicted early preterm birth with an 86% accuracy.
  • On Big Data Analysis and Preterm Birth Risk Prediction" episode on MODCAST, March of Dimes' research podcast, here .

Global Genes' RARE-X Names Winners to the Xcelerate RARE Open Science Data Challenge

Retrieved on: 
Wednesday, September 20, 2023
Sage Bionetworks, Analytics, Roche, St. Jude Children's Research Hospital, Xcelerator, Research, Rare, Scientific programming language, Global Genes, Patent, Machine learning, SAN, Data, Algorithm, RTW, Gene, Challenge, Diagnosis, Hospital, Ecosystem, AI, Team, Cord, Disease, Pharmaceutical industry, Medical device, Datavant

SAN DIEGO, Sept. 20, 2023 /PRNewswire-PRWeb/ -- The rare patient advocacy organization Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.

Key Points: 
  • Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.
  • The Xcelerate RARE Challenge brought together academic and industry researchers and data scientists to use patient-reported data for rare pediatric neurodevelopmental diseases to address unanswered research questions about rare diseases.
  • SAN DIEGO, Sept. 20, 2023 /PRNewswire-PRWeb/ -- The rare patient advocacy organization Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.
  • The Xcelerate RARE Challenge, which was focused on rare pediatric neurodevelopmental diseases, brought together academic and industry researchers and data scientists to use patient-reported data to address unanswered research questions about rare diseases.

Verily Appoints Andrew Trister, MD, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, August 1, 2023
Software, Biotechnology, Health, Data Management, Technology, Clinical Trials, Other Technology, Other Health, Sage Bionetworks, General counsel, Alzheimer's disease, COVID-19, Intelligence, Research, Biomarker, Doctor of Philosophy, Government, Organization, Digital health, Verily, Health (Apple), Machine learning, Artificial intelligence, Bill, Bill & Melinda Gates Foundation, Management, Pharmaceutical industry, MD, Apple

Verily , an Alphabet precision health technology company, today announced the appointment of Andrew Trister, MD, PhD as Chief Scientific Officer.

Key Points: 
  • Verily , an Alphabet precision health technology company, today announced the appointment of Andrew Trister, MD, PhD as Chief Scientific Officer.
  • Dr. Trister is a distinguished scientific leader with two decades of experience leveraging new technologies to translate research into product, drive population health initiatives and increase access to care.
  • He joins Verily from The Bill & Melinda Gates Foundation where he served as the Deputy Director of Digital Health and Artificial Intelligence.
  • “Andrew is an accomplished leader with a proven track record of leading transformative health technology initiatives at leading organizations focused on improving human health,” said Stephen Gillett, Chief Executive Officer at Verily.

Announcing MedPerf Open Benchmarking Platform for Medical AI

Retrieved on: 
Monday, July 17, 2023
Technology, Semiconductor, Engineering, Health Technology, Software, Manufacturing, Networks, Hardware, Health, Artificial Intelligence, Brat, Benchmarking, Sage Bionetworks, Analytics, Ben Goertzel, University, Abram Ilyich Fet, Data science, Dana–Farber Cancer Institute, HF, API, Pathology, Nature Machine Intelligence, University of Pennsylvania, Microsoft, Multimedia, Research, Synapse, Nutanix, Privacy, Radiology, Assistant, Hospital, Machine learning, Intel, Informatics, Federated, Artificial intelligence, Microsoft Azure, AI, Bias, Medical device, Glioblastoma

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    MedPerf is an open benchmarking platform that efficiently evaluates AI models on diverse real world medical data and delivers clinical efficacy while prioritizing patient privacy and mitigating legal and regulatory risks.
  • MedPerf improves medical AI by making data across the world easily and safely accessible to AI researchers, which reduces bias and improves generalizability and clinical impact.
  • “Our goal is to use benchmarking as a tool to enhance medical AI,” said Dr. Alex Karargyris, MLCommons Medical co-chair.
  • MedPerf is a foundational step towards the MLCommons Medical Working Group’s mission to develop benchmarks and best practices to accelerate medical AI through an open, neutral, and scientific approach.

Koneksa Appoints Dave Hurry as Chief Data Officer and Dr. Larsson Omberg as EVP of Data Science

Retrieved on: 
Tuesday, June 27, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Clinical Trials, Computational biology, UK Data Service, Sage Bionetworks, Drug development, Data science, Clinical trial, Raymond Lister (computer science researcher), Systems biology, Biomarker, Doctor of Philosophy, Security agency, Invention, Digital health, Patent, Cancer systems biology, Machine learning, Engineering, KTH Royal Institute of Technology, Physics, Artificial intelligence, Knowledge, Growth, Merck, Digital, Biostatistics, Cornell University, Computer science, Management, Medical imaging, Takeda, University of Texas at Austin

Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Dave Hurry as Chief Data Officer and Larsson Omberg, Ph.D., as Executive Vice President of Data Science.

Key Points: 
  • Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Dave Hurry as Chief Data Officer and Larsson Omberg, Ph.D., as Executive Vice President of Data Science.
  • They will focus on applying data science to unlock valuable insights and knowledge from clinical trial data.
  • Dr. Robert Ellis, current Head of Data Science and Co-founder, Koneksa, will transition to Head of Biomarker Exploration.
  • Dr. Larsson Omberg's appointment brings a unique blend of data science, computational biology, research management, and clinical perspective to Koneksa.

Global Genes' RARE-X Issues Open Call to Researchers to Participate in the Inaugural Xcelerate RARE Challenge

Retrieved on: 
Wednesday, May 31, 2023
Sage Bionetworks, Roche, Quality of life, Xcelerator, Research, Scientific programming language, Global Genes, Patient, CACNA1A, Machine learning, Algorithm, RTW, Challenge, RARE, Disease, Pharmaceutical industry

ALISO VIEJO, Calif., May 31, 2023 /PRNewswire-PRWeb/ -- Global Genes today announced an open call to researchers interested in participating in its inaugural Xcelerate RARE Challenge, a rare disease open science challenge focused on rare pediatric neurodevelopmental diseases.

Key Points: 
  • ALISO VIEJO, Calif., May 31, 2023 /PRNewswire-PRWeb/ -- Global Genes today announced an open call to researchers interested in participating in its inaugural Xcelerate RARE Challenge, a rare disease open science challenge focused on rare pediatric neurodevelopmental diseases.
  • The Xcelerate RARE Challenge brings together academic and biopharmaceutical industry researchers and data scientists to use patient reported data to address unanswered research questions about rare diseases.
  • "With this Xcelerate RARE Challenge, our goal is to advance rare disease understanding and meaningful therapeutic research for rare diseases through open sharing of robust data, and collaboration."
  • Without the generosity and unwavering support of the sponsors and partners, the Xcelerate RARE Challenge would not have been possible.

New Resources Remove Obstacles to Deliver DE&I in Digital Clinical Trials

Retrieved on: 
Wednesday, February 15, 2023
Organization, GSK, Woman, Janssen, Commissioner, American Kidney Fund, Scripps Research, Safety, Patient, Clinical trial, DE, Dime, Food, Silvaco Data Systems v. Intel Corp., Risk, Failure, DEI, FDA, Research, US Food Sovereignty Alliance, Sage Bionetworks, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech

BOSTON, Feb. 15, 2023 /PRNewswire/ -- As part of a pre-competitive collaboration with digital health leaders, the Digital Medicine Society (DiMe) launched a suite of new, free resources to advance diversity, equity, and inclusion (DE&I) in digitized clinical trials.

Key Points: 
  • The digital tools available to us today can position us to stop admiring the problem of non-representative clinical trials and actually address the problem.
  • Specific Actions Workbook - recommendations on how to use specific digital tools to improve and increase enrollment and retention of diverse participants in digitized clinical trials.
  • They are already leading the field, with case studies demonstrating how DiMe resources, digital tools, and a commitment to a clinical trials enterprise that serves all people can effectively deliver diversity, equity, and inclusion in digitized clinical trials.
  • We invite new resource users to join us in sharing the ways you are delivering DE&I in clinical trials through DiMe's "Resources in Action" case study hub .

RARE-X to Launch an Open Science Data Challenge to Address Rare Neurodevelopmental Diseases

Retrieved on: 
Tuesday, January 17, 2023
Disease, Roche, Algorithm, Scientific programming language, Communication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Global Genes, Machine learning, Prom, Patient, Diagnosis, Food, Research, Artificial intelligence, Open science data, Xcelerator, RTW, Sage Bionetworks, Pharmaceutical industry

ALISO VIEJO, Calif., Jan. 17, 2023 /PRNewswire-PRWeb/ -- RARE-X, the Global Genes collaborative platform for rare disease patients to share their data to accelerate the development of diagnoses and treatments, today announced its inaugural Xcelerate RARE: An Open Science Data Challenge to bring together researchers and data scientists to use patient-provided data to address unanswered research questions about rare diseases.

Key Points: 
  • The first Xcelerate RARE challenge will launch in the spring of 2023 and will focus on rare pediatric neurodevelopmental diseases.
  • ALISO VIEJO, Calif., Jan. 17, 2023 /PRNewswire-PRWeb/ -- RARE-X, the Global Genes collaborative platform for rare disease patients to share their data to accelerate the development of diagnoses and treatments, today announced its inaugural Xcelerate RARE: An Open Science Data Challenge to bring together researchers and data scientists to use patient-provided data to address unanswered research questions about rare diseases.
  • "The Open Science Data Challenge is like a long-form hackathon," said Karmen Trzupek, Senior Director of Scientific Programs for Global Genes.
  • Or listen to the RARE-Xtra Podcast on An Open Science Data Challenge to Address Rare Neurodevelopment Diseases.

Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Retrieved on: 
Tuesday, August 2, 2022
Biotechnology, General Health, Infectious Diseases, Health, Clinical Trials, Rockefeller University, Diagnosis, Precision medicine, Columbia University Irving Medical Center, University, Corporation, Helix, Degenerative disease, Learning, U.S. Securities and Exchange Commission, Hematology, Forward-looking statement, SEC, Research, Coronavirus Scientific Advisory Board (Turkey), Board, Pediatrics, Biotechnology, Company, Translation, Board of directors, Sage Bionetworks, Patient, Nasdaq, Weill Cornell Medicine, Lists of diseases, Cornell University, Columbia University, Economics, Pharmaceutical industry, Medicine, Genetics, Biochemistry

Wendy is a tremendous addition to our Board of Directors.

Key Points: 
  • Wendy is a tremendous addition to our Board of Directors.
  • We look forward to learning from her expertise and insights, said Martin Mackay, Ph.D., Chairman and Chief Executive Officer at Rallybio.
  • On behalf of our directors, I am pleased to welcome Wendy to Rallybios Board.
  • She is a board certified clinical and molecular geneticist with more than 20 years of experience in human genetic research.